Controversy and Research Progress between CAR-T Therapy and T-Cell Lymphomas Triggered by the U.S. FDA’s Boxed Warning

Yang Xu, Meng Shufang

Chinese Pharmaceutical Affairs ›› 2025, Vol. 39 ›› Issue (8) : 919-928.

PDF(1021 KB)
PDF(1021 KB)
Chinese Pharmaceutical Affairs ›› 2025, Vol. 39 ›› Issue (8) : 919-928. DOI: 10.16153/j.1002-7777.2025-05-0016
Research Progress

Controversy and Research Progress between CAR-T Therapy and T-Cell Lymphomas Triggered by the U.S. FDA’s Boxed Warning

    {{javascript:window.custom_author_en_index=0;}}
  • {{article.zuoZhe_EN}}
Author information +
History +

HeighLight

{{article.keyPoints_en}}

Abstract

{{article.zhaiyao_en}}

Key words

QR code of this article

Cite this article

Download Citations
{{article.zuoZheEn_L}}. {{article.title_en}}[J]. {{journal.qiKanMingCheng_EN}}, 2025, 39(8): 919-928 https://doi.org/10.16153/j.1002-7777.2025-05-0016

References

References

{{article.reference}}

Funding

RIGHTS & PERMISSIONS

{{article.copyrightStatement_en}}
{{article.copyrightLicense_en}}
PDF(1021 KB)

Accesses

Citation

Detail

Sections
Recommended

/